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htcense.Abstract COPD is no longer considered to affect only the lungs and airways but also the rest of
the body. The systemic manifestations of COPD include a number of endocrine disorders such as
those involving the pituitary, thyroid, gonads, adrenals and pancreas.
The aim of this work is to detect the endocrinal and inﬂammatory changes in COPD patients dur-
ing stability of the disease and the effect of acute exacerbation on these changes.
Subjects and methods: Twenty acute exacerbated COPD (AECOPD) male patients with acute
respiratory failure (ARF) were included in this study as a patient group and a control group which
included 10 healthy age-matched males with normal pulmonary functions and without any of the
exclusion criteria. For patients enrolled in this study, measurement of serum levels of sex hormones
[total testosterone, luteinizing hormone (LH) and follicle-stimulating hormone (FSH)], insulin like
growth factor-1 (IGF-1) and C-reactive protein (CRP) were done on admission and 1 month after
hospital discharge. For healthy group, the previous measurements were done once only.
Results: There were statistically signiﬁcant decrease in serum testosterone and IGF-1 levels in
patients after stabilization than those in the control group with more decrease of their levels during
exacerbation and the difference between their levels in patients during exacerbation and after stabil-
ization was statistically highly signiﬁcant. As regards serum LH and FSH, there were statistically
highly signiﬁcant increase in their levels in COPD patients during exacerbation than those in the con-
trol group but there were non-signiﬁcant differences in these hormones levels between the patients
after stabilization and the control group. As regards serumCRP, there was highly signiﬁcant increase
in its serum level in patients in both exacerbation and after stabilization than that in the control group.
The level of CRP in patients during exacerbation was higher than that after stabilization and the dif-
ference was statistically highly signiﬁcant. As regards disease severity, there were statistically highly
signiﬁcant decrease in testosterone level in severe to very severe COPDpatient group than that inmild01273477882.
hoo.com (A. Shaker).
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82 A. Shaker et al.tomoderate one. There was also statistically signiﬁcant decrease in serum IGF-1 level in severe to very
severe COPD patient group than that in mild to moderate one. There was statistically highly signiﬁ-
cant increase in serum CRP level in severe to very severe COPD patient group than that in mild to
moderate one. On the other hand, there was statistically non-signiﬁcant increase in serum LH and
FSH levels in severe to very severe CPOD patient group than those in mild to moderate one. There
were statistically highly signiﬁcant positive correlations between serum testosterone levels and both
FEV1% predicted and PaO2. There were also statistically highly signiﬁcant positive correlations
between serum IGF-1 levels and bothFEV1%predicted andPaO2 and also between serumCRP levels
and PaCO2 in patients during exacerbation. Also during exacerbation, there was statistically highly
signiﬁcant negative correlation between serum CRP levels and FEV1% predicted.
Conclusion: COPD leads to alterations in serum levels of sex hormones (testosterone, LH and
FSH), IGF-1 and CRP. There was decrease in testosterone hormone levels of male stable COPD
patients and this decrease was more evident, with compensatory increase in LH and FSH hormones
levels, during exacerbation period when hypoxemia is more signiﬁcant. CRP level is increased even in
stable COPD and this rise is magniﬁed with increased disease severity. IGF-1 decreased in stable
COPD patients with more decrease in its level during acute exacerbation.
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
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COPD is associated with low grade systemic inﬂammation that
may be responsible for the systemic effects of the disease; mal-
nutrition, muscle wasting, osteoporosis, cardiovascular dis-
ease, type II diabetes mellitus, anemia and depression [1].
COPD is no longer considered to affect only the lungs and
airways but also the rest of the body. The systemic manifesta-
tions of COPD include a number of endocrine disorders such
as those involving the pituitary, thyroid, gonads, adrenals
and pancreas [3]. There are several studies examining the endo-
crine system of COPD patients, generally in stable cases [4].
Growth hormone provides stimulation of muscle growth
and development. Growth hormone exerts its effects primarily
by increasing levels of insulin-like growth factors (IGF).
Increasing age, systemic corticosteroids commonly used to
treat COPD exacerbations are known to down-regulate the
growth hormone system [5]. The data that exist suggest that
IGF-1 levels in stable COPD patients tend to be low consistent
with the impression that the growth hormone axis is sup-
pressed by chronic disease [6]. On the other hand, a few studies
suggested increased growth hormone concentrations in COPD
and especially in hypoxemic COPD [7].
Decreased anabolic hormone levels are commonly de-
scribed in several chronic or critical illnesses including; chronic
respiratory diseases [8]. Peripheral muscle wasting, osteoporo-
sis, sexual dysfunction, immunological alterations, memory
loss, diminished energy and vitality are among the clinical con-
sequences of hypogonadal state [4,9]. The aim of this work is
to detect the endocrinal and inﬂammatory changes in COPD
patients during stability of the disease and the effect of acute
exacerbation on these changes.Subjects and methods
This study was conducted during the period from May 2009 to
October 2010 at Chest and Clinical Pathology Departments,
Zagazig University Hospitals.
Subjects included in this study comprised twenty acute
exacerbated COPD (AECOPD) male patients with acuterespiratory failure (ARF) as a patient group and ten healthy
age-matched males with normal pulmonary function and with-
out any of the exclusion criteria as a control group.
The diagnosis of COPD and acute exacerbation of COPD
was established according to GOLD criteria [10]. Patients with
acute exacerbation of COPD admitted to respiratory intensive
care unit (RICU) were enrolled in this study. Diagnostic crite-
ria for ARF were respiratory acidosis (pH < 7.35, Pa-
CO2 > 45 mmHg) and PaO2/FiO2 < 200 and/or evidence of
respiratory distress (respiratory rateP 30/min, accessory
respiratory muscle use, paradoxical breathing or intercostal
muscle retraction) [11].
Spirometric classiﬁcation of disease severity (mild, moder-
ate, severe and very severe) was done according to GOLD cri-
teria [10] after stabilization (1 month after hospital discharge).
Exclusion criteria
Patients who need mechanical ventilation or who use drugs
may interfere with serum hormone levels, infections, malig-
nancy, signiﬁcant cardiac, renal, hepatic, metabolic or endo-
crine disturbances or neurological diseases were excluded [12] .
All enrolled individuals were subjected to the following:
(1) Thorough medical history stressing on smoking habit.
(2) Full clinical examination.
(3) Plain chest X-ray (postero-anterior and lateral views).
(4) Routine laboratory investigations (CBC, liver and kid-
ney functions).
(5) Pulmonary function tests: were done on the ﬁrst day of
admission and 1 month after hospital discharge (after
stabilization). Forced expiratory volume in one second
(FEV1) and forced vital capacity (FVC) were mea-
sured with Sensor Medicus 2450 computerized pul-
monary function apparatus. One month after
hospital discharge, patients with FEV1P 80% of pre-
dicted value were considered mild,
50% 6 FEV1 < 80% of predicted value were consid-
ered moderate, 30% 6 FEV1 < 50% of predicted
value were considered severe and FEV1 < 30% of pre-
dicted value were considered very severe [10].
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ﬁrst day of admission and 1 month after hospital dis-
charge (after stabilization). It was done to check arte-
rial oxygen tension (PaO2), arterial carbon dioxide
tension (PaCO2) and arterial pH using blood gas ana-
lyzer (ABL-330- Radiometer Copenhagen).
(7) Serum CRP estimation: [13]
BN ProSpec was used in CRP estimation. Polystyrene par-
ticles coated with monoclonal antibodies speciﬁc to human
CRP are aggregated when mixed with samples containing
CRP. These aggregates scatter a beam of light passed through
the sample. The intensity of the scattered light is proportional
to the concentration of the relevant protein sample. The result
is evaluated by comparison with a standard of known concen-
tration (CArdioPhase DADE BEHR ING, Newark. USA).
(8) Serum IGF-1 measurement: [14]
IGF-1 was determined using ELISA kit from BioSource,
Belgium. The technique includes an extraction step in which
IGF-1 is separated from its binding protein by ethanol–HCl
acid extraction solution. The technique uses antibodies with
high afﬁnity and speciﬁcity for two different epitopes on
IGF-1. A ﬁrst monoclonal anti-IGF-1 antibody bound to a
polystyrene well will capture the IGF-1 of the sample in the
presence of a second alkaline phosphatase conjugated mono-
clonal anti-IGF-1 antibody. Following incubation and wash-
ing, the chromogen/substrate was added and intensity of
color was measured at 405 nm.
(9) Serum total testosterone, LH and FSH assay: [15].
They were measured using electro-chemiluminescence
immunoassay on Cobase 411. The assay employs two mono-
clonal antibodies both speciﬁcally directed against the param-
eters measured one is biotinylated (interact with streptavidin-
coated microparticles) and the other labeled with ruthenium
(responsible for chemiluminescence emission).Table 1 Demographic characteristics of the studied subjects at tim
Parameter Patients group (n= 20)
Age (years) 57.34 ± 12.65
BMI (kg/m2) 23.61 ± 4.86
Smoking (pack-year) 48.57 ± 15.37
Table 2 Pulmonary function tests and arterial blood gas analysis o
hospital discharge (after stabilization) and controls.
Parameter During exacerbation patients (n= 20) A
FEV1% predicted 46.39 ± 12.15 5
FVC% predicted 50.8 ± 13.14 8
FEV1/FVC 48.3 ± 13.96 5
pH 7.31 ± 0.06
PaO2 (mmHg) 46.21 ± 11.32 8
PaCO2 (mmHg) 75.23 ± 16.49 4
* P-value is obtained by comparison of patients during exacerbation (onFor the healthy group, the previous measurements were
done once only.
All patients were followed until hospital discharge and
1 month later.
For patients, blood samples were collected at the ﬁrst day of
RICU admission and 1 month after hospital discharge with stop-
page of steroid therapy (if it is continued after hospital discharge)
at least 5 days before hormonal measurement. After centrifuga-
tion, sera were kept frozen at 80 C until assayed [11].
Statistical analysis
Statistical analysis was performed with the SPSS statistical
software package (SPSS Inc., Chicago, IL).
Data presented by mean ± SD for quantitative continuous
data was calculated by one way analysis for variance (F test).
Comparing mean values of paired data of patients during
exacerbation and after stabilization were done by paired (t)
test, also comparison of mean values of patients data whether
during exacerbation or after stabilization with controls were
done by independent (t) test.
Correlation coefﬁcient (r) were calculated for testing associ-
ation between quantitative variables. P-value < 0.05 is consid-
ered signiﬁcant.
Results
Table 1 showed demographic data of the studied subjects at
time of admission. There were statistically non-signiﬁcant dif-
ferences regarding age, BMI and pack-year of smoking be-
tween patients and control groups.
Table 2 showed statistically highly signiﬁcant differences
regarding FEV1% predicted (P= 0.006), PaO2 (P= 0.001)
and PaCO2 (P= 0.001) when these parameters were com-
pared in patients during exacerbation (at time of admission)
and after stabilization (1 month after hospital discharge).
Table 3 showed statistically highly signiﬁcant differences
(P= 0.001) in patients during exacerbation and aftere of admission.
Control group (n= 10) P-value
55.58 ± 13.21 0.8
25.32 ± 5.72 0.39
46.39 ± 13.46 0.71
f patients on admission (during exacerbation) and 1 month after
fter stabilization (n= 20) Controls (n= 10) P-value*
4.63 ± 13.29 91.23 ± 14.46 0.006
5.21 ± 25.32 94.05 ± 15.38 0.001
9.87 ± 15.28 80.4 ± 9.53 0.006
7.42 ± 0.08 7.37 ± 0.14 0.01
0.24 ± 20.47 94.54 ± 5.93 0.001
2.83 ± 11.73 37.34 ± 3.51 0.001
admission) and after stabilization (1 month after hospital discharge).
Table 3 Serum sex hormones, IGF-1 and CRP levels on admission (during exacerbation) and 1 month after hospital discharge (after
stabilization) in patient group in comparison to controls.
Parameter During exacerbation
(n= 20)
After stabilization
(n= 20)
Controls
(n= 10)
P-value
*
P-value
**
P-value
***
Serum testosterone
(ng/ml)
1.4 ± 0.03 2.5 ± 0.71 5.7 ± 1.72 0.001 0.02 0.03
Serum LH (mlU/ml) 14.26 ± 3.21 6.31 ± 2.01 5.03 ± 1.53 0.001 0.0001 0.09
Serum FSH (mlU/
ml)
14.03 ± 3.01 6.98 ± 2.23 5.63 ± 1.62 0.001 0.0001 0.14
Serum IGF-1 (ng/
ml)
56.23 ± 17.4 93.61 ± 18.8 135.21 ± 24.4 0.001 0.0001 0.0001
Serum CRP (mg/dl) 43.7 ± 5.09 7.35 ± 1.1 0.3 ± 0.01 0.001 0.0001 0.0001
* P-value is obtained by the comparison of patients during exacerbation and after stabilization.
** P-value is obtained by the comparison of patients during exacerbation and controls.
*** P-value is obtained by the comparison of patients after stabilization and controls.
84 A. Shaker et al.stabilization as regards serum sex hormones, IGF-1 and CRP
levels. There was statistically signiﬁcant decrease in serum tes-
tosterone level in patients during exacerbation (P= 0.02) and
also after stabilization (P= 0.03) than that in the control
group. Statistically highly signiﬁcant decrease in serum IGF-
1 level (P= 0.0001) in patients during exacerbation and after
stabilization than that in control group was observed. As re-
gards serum LH and FSH, there were statistically highly signif-
icant increase in their levels in COPD patients during
exacerbation than that in the control group (P= 0.0001) but
there were non- signiﬁcant differences (P= 0.09) and
(P= 0.14) in these hormones levels respectively between the
patients after stabilization and the control group. As regards
serum CRP, there was highly signiﬁcant increase in its serum
level in patients both during exacerbation and after stabiliza-
tion than that in control group (P= 0.0001).
Table 4 showed statistically highly signiﬁcant decrease in
testosterone level (P= 0.0001) in severe to very severe COPD
patient group than that in mild to moderate one. There was
also statistically signiﬁcant decrease in serum IGF-1 level in se-
vere to very severe COPD patient group than that in mild to
moderate one (P= 0.01). There was highly signiﬁcant increase
in serum CRP level in severe to very severe COPD patient
group than that in mild to moderate one (P= 0.0001) butTable 4 Sex hormones, IGF-1 and CRP levels in patients group du
Parameter Mild to moderate COPD (n= 9)
Serum testosterone (ng/ml) 2.7 ± 0.6
Serum LH (mlU/ml) 6.53 ± 2.12
Serum FSH (mlU/ml) 6.63 ± 2.11
Serum IGF-1 (ng/ml) 99.4 ± 17
Serum CRP (mg/dl) 2.6 ± 0.61
Table 5 Correlation coefﬁcient between each of serum sex hormon
and PaCO2 (mmHg) during exacerbation.
Serum testosterone Serum LH
FEV1% predicted 0.58
** 0.23
PaO2 (mmHg) 0.71
** 0.32
PaCO2 (mmHg) 0.46* 0.28
* P< 0.05.
** P< 0.01.the difference was statistically non-signiﬁcant as regards serum
LH and FSH levels (P= 0.67) and (P= 0.69) respectively be-
tween both groups.
Table 5 showed statistically highly signiﬁcant positive cor-
relations between serum testosterone levels and both FEV1%
predicted and PaO2, serum IGF-1 levels and both FEV1% pre-
dicted and PaO2 and also between serum CRP levels and
PaCO2 in patients during exacerbation. Also, there was statis-
tically highly signiﬁcant negative correlation between serum
CRP levels and FEV1% predicted and this negative correlation
was signiﬁcant between serum CRP levels and PaO2 and be-
tween serum testosterone levels and PaCO2 in patients during
exacerbation.
Table 6 showed statistically signiﬁcant positive correla-
tion between serum testosterone levels and FEV1% pre-
dicted. But, there were statistically signiﬁcant negative
correlations between serum CRP levels and both FEV1%
predicted and PaO2.
Discussion
Decreased anabolic hormone levels are commonly described
in several chronic or clinical illnesses including; chronicring stabilization regarding to disease severity.
Severe to very severe COPD (n= 11) P-value
1.4 ± 0.4 0.0001
7.02 ± 2.85 0.67
7.01 ± 2.12 0.69
75.8 ± 19 0.01
8.6 ± 1.41 0.0001
es, IGF-1 and CRP levels and FEV1% predicted, PaO2 (mmHg)
Serum FSH Serum IGF-1 Serum CRP
0.28 0.74** 0.71**
0.33 0.70** 0.51*
0.22 0.21 0.59**
Table 6 Correlation coefﬁcient between each of serum sex hormones, IGF-1 and CRP levels and FEV1% predicted, PaO2 (mmHg)
and PaCO2 (mmHg) after stabilization.
Serum testosterone Serum LH Serum FSH Serum IGF-1 Serum CRP
FEV1% predicted 0.53
* 0.43 0.26 0.41 0.49*
PaO2 (mmHg) 0.22 0.14 0.36 0.39 0.45*
PaCO2 (mmHg) 0.28 0.06 0.29 0.35 0.16
* P< 0.05.
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bolic hormone levels are low in COPD, although the underly-
ing mechanisms are unclear [16]. In COPD, little is known
about circulating IGF-1 concentrations. Some authors found
a decrease in IGF-1, others found an increase [6]. The present
study was performed to detect the endocrinal and inﬂamma-
tory changes in COPD patients during stability of the disease
and the effect of acute exacerbation on these changes.
We found statistically highly signiﬁcant differences
(P= 0.001) between patients during exacerbation and after
stabilization as regards serum sex hormones, IGF-1 and
CRP levels. Also, the differences were statistically highly sig-
niﬁcant (P= 0.0001) as regards serum LH, FSH, IGF-1 and
CRP levels between patients during exacerbation and controls
and also between patients after stabilization and controls
regarding serum IGF-1 and CRP levels only (Table 3). Also,
in our study, regarding disease severity, there was statistically
highly signiﬁcant decrease in testosterone level (P= 0.0001) in
severe to very severe COPD patient group than that in mild to
moderate one but the difference was statistically non-signiﬁ-
cant as regards serum LH and FSH levels (P= 0.67) and
(P= 0.69) respectively between both groups. Regarding sex
hormones, normally when testosterone level is decreased, a
negative feedback of sex hormones on the hypothalamic-pitu-
itary axis is lost and secretion of gonadotrophins (LH and
FSH) increases [17].
Our results of sex hormones may be due to several mecha-
nisms including; hypoxemia [18], obesity, glucocorticoid ther-
apy, atrophy of leydig cells and increased cytokine
concentrations [19,20].
Systemic inﬂammation has been suggested as a possible
cause of low circulating testosterone concentrations in male
patients with COPD [16] and this explains the statistically sig-
niﬁcant decrease of serum testosterone levels in COPD patients
after stabilization than those in controls (Table 3).
Interestingly, there is a regulating loop between proinﬂam-
matory cytokines and anabolic steroids. Increased levels of
proinﬂammatory cytokines as in acute exacerbation of COPD
reduce testosterone secretion by interfering with leydig cell
function [21].
Hypotestosteronemia in our study was accompanied with
statistically highly signiﬁcant increase in serum LH and FSH
levels in patients during exacerbation than those in patients
after stabilization and those in the control group (Table 3)
and this testicular dysfunction is called hyper-gonadotrophic
hypogonadism [11]. It depicts an increased compensatory
gonadtrophins secretion from the hypothalamic-pituitary axis
in order to correct the low circulating testosterone level [17].
In fact, a decrease in circulating testosterone concentrations
and a compensatory increase in the circulating gonadotrophinshave been reported in healthy elderly men [22] and in patients
with COPD [4].
Our results are in consistence with Akbas et al. [11] who re-
ported reduced testosterone levels in COPD patients and sug-
gested that hypogonadism may be due to a primary testicular
atrophy in COPD.
One of the suggested underlying factors for hypogonadism
is hypoxemia, which is present in a proportion of COPD pa-
tients [12]. Gosney [19] found smaller testis volume and ley-
dig-cell atrophy in necropsy of COPD patients and suggested
that this atrophy may be a consequence of hypoxic inhibition
of pituitary synthesis or release of LH. Semple et al. [23]
suggested that hypoxemia produces abnormalities of hypotha-
lamic–pituitary–testicular function, rather than primary testic-
ular dysfunction and they concluded that these hypoxemia-
induced changes were reversible as testosterone concentration
increased signiﬁcantly in men recovering from a severe exacer-
bation of COPD. The ﬁndings of Aasebo et al. [24] supported
these data as they showed that long-term oxygen treatment in-
creased sexual function and testosterone levels.
Also, supporting to these data, serum testosterone was
measured low in men exposed to high-altitude hypoxia [19],
in patients with hypoxemic idiopathic pulmonary ﬁbrosis
and hospitalized hypoxemic COPD patients [18].
Another possible cause of the observed hypogonadism may
be glucocorticoid-induced suppression of the adrenals, a direct
inhibitory effect via testicular glucocorticoid receptors or de-
creased testosterone biosynthesis via reduced content of LH
receptors in leydig cells [25].
Karadag et al. [12] study is in consistence with our results as
they found signiﬁcant differences in sex hormone levels during
stable and exacerbation phases of COPD.
The decrease in androgens and compensatory increase in
gonadotrophins during exacerbation phase when hypoxemia
is more signiﬁcant and subsequent regression of these altera-
tions when disease is stabilized may be accepted as a compen-
satory reaction of hypothalamo–pituitary–gonadal axis
against suppression of testicular function in COPD [12]. This
may explain our results.
In this study, after stabilization of the disease, sex hor-
mones levels returned back but didn’t reach to normal levels
as in controls. These results may be explained by the presence
of low-grade systemic inﬂammation in stable COPD patients
and there are high levels of proinﬂammatory cytokines as
IL-6, TNF-a and CRP in stable COPD and these cytokines
cause sex hormones alteration [11].
With disease improvement, suppressed hormones (testoster-
one) rebound as synthesis and secretion of them increase
[23,26]. The normalization of hormones may take a long time.
Elevation of testosterone to normal values was reported to
86 A. Shaker et al.take 2–12 months [27]. A return of LH and FSH to normal
ranges can take as long as the rise in testosterone [28].
In contrary, Svartberg et al. [29] reported that men having
chronic bronchitis or emphysema didn’t have reduction in tes-
tosterone levels, thus they speculate that it is not the disease
per se that affects the hormone levels but the actual level of
pulmonary function. Also, they hypothesize that the gradual
decline in FEV1% predicted is followed by a decline in testos-
terone and this may explain the decrease in serum testosterone
levels with increasing severity of COPD. Our work is in agree-
ment with Makarevich [30] who concluded that the intensity of
sex hormone changes were correlated with the stage of COPD.
As the severity of the disease increased, testosterone decreased
and LH, FSH increased compensatively and they suggested
that anabolic hormonal deﬁciency is a surrogate of disease
severity especially in men.
In disagreement with our results, Laghi et al. [4] noticed in
their study, that the severity of lung disease didn’t predict the
hormonal abnormalities, making chronic disease an unlikely
cause of hypogonadism.
In the lung, CRP has protective functions in innate immune
responses against bacteria and apoptotic cells. CRP enters the
lung from plasma and is primarily produced by hepatocytes in
response to IL-6 stimulation. Activated epithelial cells and in-
creased numbers of alveolar macrophages and other inﬂamma-
tory cells in COPD may release IL-6 into the circulation. This
stimulates an acute-phase response and increases the level of
plasma CRP [31].
Regarding serum CRP results in this study, the statisti-
cally highly signiﬁcant increase of serum CRP levels in pa-
tients during exacerbation than those after stabilization is
due to the fact that CRP levels rise rapidly during infection
or after injury to just decline after the initial stimulus has
vanished [32]. Also, we found that after stabilization of the
disease, serum CRP levels were still higher in stable COPD
patients than those in controls. These results may be ex-
plained by that the focus of systemic inﬂammation in COPD
patients is still unclear. Several theories were previously
suggested, including; local pulmonary inﬂammation due to
actual or previous smoking, oxidative stress and tissue hypox-
ia known to increase cytokine levels [33]. Gan et al. [34] re-
ported that individuals with chronic airﬂow limitation had
signiﬁcantly raised levels of CRP, ﬁbrinogen, leucocytes and
TNF-a indicating that persistent systemic inﬂammation is
present in COPD. Even among non-current smokers, there
was evidence for low-grade systemic inﬂammation in those
with chronic airﬂow limitation. This suggests that, once
COPD develops, cessation of smoking may not fully attenu-
ate the inﬂammatory process associated with this condition.
Increased serum CRP in stable COPD seems to be reduced
by treatment with an inhaled corticosteroids [35].
Our result is in agreement with Pinto-Plata et al. [36]. They
reported that the stable COPD patients had higher levels of
inﬂammatory markers like CRP rather than smoker and
non-smoker control groups.
Of all the investigated inﬂammatory markers in Piehl-Aulin
et al. [37] study, serum CRP levels were signiﬁcantly increased
even in mild COPD (GOLD stage I) and remained signiﬁcantly
increased at the moderate and severe CODP stages and our re-
sults match this study.
The evidence for the presence of systemic inﬂammatory
process was manifested in otherwise clinically stable patientsby an early and sustained rise of serum CRP with ascending
disease severity [37].
Many previous studies are in agreement with our results of
CRP and severity of COPD. de Torres et al. [38] reported that
serum CRP level was signiﬁcantly increased by aggravation of
COPD reﬂecting the systemic inﬂammatory process in patients
with severe disease. Also, they demonstrated that high CRP
levels in COPD patients are due to the greater degree of airway
obstruction and disease severity and CRP levels of patients
who died tended to be higher than those who survived.
IGF-1 has been implicated in several important functions
such as cell differentiation, growth and maintenance of skeletal
muscle [39].
In our study, the highly signiﬁcant decrease in IGF-1 levels
in patients during acute exacerbation than those after stabiliza-
tion and also in stable COPD patients than those in controls
may be due to the fact that the bioavailability and the effects
of IGF-1 are inﬂuenced by IGF-1 binding protein (IGFBP).
Therefore, an increase in circulating levels of these proteins
may decrease the levels of free IGF-1 [39]. Cytokines increase
IGFBP-1 and IGFBP-4 and this results in a decreased free
IGF-1 fraction. IL-6 performs its suppressive activity on
IGF-1 via increased production of its binding protein [40].
Growth hormone (GH) mediates its major metabolic effects
predominantly through IGF-1. The GH axis is suppressed in
chronic diseases and this may partly explain the low IGF-1 lev-
els and, also may explain that after stabilization of the COPD
patients, IGF-1 levels increases but still remained lower than
levels in healthy controls [41].
Our results are in consistence with Coskun et al. [42] and
Kythreotis et al. [41]. They reported lower levels of serum
IGF-1 in stable COPD patients than in healthy subjects and
these levels tend to be lower in patients with COPD
exacerbation.
In contrary, Debigare et al. [43] demonstrated an increase
in circulating GH and IGF-1 in COPD patients. The increase
in GH might reﬂect a non-speciﬁc response of the body to
stress (hypoxemia) [42].
As the disease severity increases, the local inﬂammation is
more pronounced and the proinﬂammatory cytokines in-
creases, so the more the decrease of serum IGF-1 levels which
is due to increase of IGFBP [44]. This may explain the signif-
icant decrease of serum IGF-1 level in severe to very severe
COPD patient group than that in mild to moderate one. In
consistence, Coskun et al. [42] found that IGF-1 levels were
signiﬁcantly decreased in very severe COPD patients compared
to mild to moderate COPD patients.
Some authors advocate that low levels of IGF-1 might be
increasing the severity of the disease particularly in COPD pa-
tients by adversely affecting the respiratory muscle [43].
Regarding correlation coefﬁcient during exacerbation,
there were statistically highly signiﬁcant positive correlations
between each of serum testosterone and IGF-1 levels and both
FEV1% predicted and PaO2 and between serum CRP levels
and PaCO2 (P< 0.01). Also, there were statistically signiﬁcant
negative correlation between serum testosterone levels and
PaCO2 and between serum CRP levels and PaO2 (P< 0.05)
(Table 5).
Regarding correlation coefﬁcient after stabilization of the
disease, there were statistically signiﬁcant positive correlation
between serum testosterone levels and FEV1% predicted and
statistically signiﬁcant negative correlations between serum
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both FEV1% predicted and PaO2 (P< 0.05) (Table 6).
As regards serum testosterone correlations, our results are
in agreement with Svartberg et al. [29] who concluded that
both total and free testosterone were positively and indepen-
dently associated with FVC% predicted and men with severe
pulmonary obstruction (FEV1 < 50% predicted in combina-
tion with FEV1/FVC < 70%) had lower testosterone levels
compared with the remaining study cohort.
Makarevich [30] assessed relation of sex hormone status
and the stage of COPD. They concluded that the intensity of
sex hormone changes were correlated with the stage of COPD.
Semple et al. [18] found low testosterone levels in acutely ill,
hospitalized COPD patients with hypoxemia and reported that
the degree of testosterone suppression was correlated to sever-
ity of arterial hypoxemia and hypercapnia and these results
match our study results. Also, Karadag et al. [12] reported
that, in COPD exacerbation, testosterone was positively corre-
lated to PaO2. In follow-up measurements, testosterone in-
creased and LH decreased in parallel with the improvement
in arterial blood gases.
In contrary, Debigare et al. [43] and Laghi et al. [4] didn’t
demonstrate an association between testosterone concentra-
tions and PaO2. The lack of association is due to serum testos-
terone levels tend not to fall to the hypogonadal range until
PaO2 drops below 55 mmHg [18], a threshold crossed by only
3 of their patients while breathing room air.
CRP (an inﬂammatory marker) has generated in the COPD
ﬁeld. CRP is an acute-phase reactant that increases in a very
sensitive but non-speciﬁc way in most forms of tissue damage,
inﬂammation and infection, all are very dynamic processes in
patients with COPD [2].
As regards serum CRP correlations, our results in consis-
tence with Gan et al. [45] who reported that elevated CRP is
associated with decline in lung function and worsening of
chronic COPD. Also, Rasmussen et al. [46] concluded that
there is an association between inﬂammation in COPD and
FEV1 and FVC decline.
Our results also, agreed the results of de Torres et al. [38]
study who reported that in stable COPD patients, CRP levels
correlated mainly with physiological parameters, such as
FEV1, FVC and PaO2 and explained the inverse correlation
between CRP levels and PaO2 as hypoxemia triggers oxidative
stress and inﬂammation in COPD patients.
In contrary, Pinto-Plata et al. [36] demonstrated that there
was no association between selected pulmonary function test
measurements (FEV1, TLCO) and CRP levels in COPD
patients.
Regarding serum IGF-1 correlations, our results are in
agreement with Spruit et al. [47] who reported that lower levels
of serum IGF-1 were correlated with lower levels of FEV1 in
COPD patients and this result may be supported by that
IGF-1 levels tend to be low in patients with COPD, which
might be consistent with the impression that the growth hor-
mone (GH) axis is suppressed by severe chronic disease[6].
Also, as regards PaO2, many studies are in consistence with
our work. Ursavas et al. [48] reported that the positive corre-
lation between the decrease in IGF-1 levels and the decrease
of PaO2 may be due to several mechanisms as; acute hypox-
emia decreases the rate of IGF-1 synthesis, the clearance rate
of IGF-1 may have increased, acute hypoxemia signiﬁcantly
increased plasma concentration of IGFBP-1 which decreasesthe free IGF-1 fraction and also chronic hypoxemia could have
a direct effect on transcription of IGF-mRNA, similar to its ef-
fect on transcription of other proteins [49].Conclusion
COPD leads to alterations in serum levels of sex hormones,
IGF-1 and CRP. There was decrease in testosterone hormone
levels of male stable COPD patients and this decrease was
more evident, with compensatory increase in LH and FSH
hormones levels, during exacerbation period when hypoxemia
is more signiﬁcant. CRP level is increased even in stable COPD
and this rise is magniﬁed with increased disease severity. IGF-1
decreased in stable COPD patients with more decrease in its le-
vel during acute exacerbation.References
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